QuidelOrtho Corporation se especializa en la creación y producción de soluciones de pruebas diagnósticas, abordando una amplia gama de necesidades de pruebas ...
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal
QuidelOrtho Corporation is a public healthcare company listed on the Nasdaq Global Select Market under the symbol QDEL. Headquartered at 9975 Summers Ridge Road in San Diego, California, the company is one of the larger global providers of in vitro diagnostic products. QuidelOrtho was created through the combination of Quidel Corporation and Ortho Clinical Diagnostics, bringing together Quidel's point-of-care and molecular-testing expertise with Ortho's long-standing capabilities in clinical laboratory diagnostics and transfusion medicine. The company traces its Quidel history to 1979, while the broader Ortho diagnostic heritage extends back much further.
The business is organized around several principal areas. Its Labs division supplies clinical chemistry and immunoassay instruments, reagents, consumables, and related tests used to analyze bodily fluids and proteins. These products support disease detection, patient assessment, treatment management, and monitoring of disease progression. The Transfusion Medicine business provides immunohematology and infectious-disease screening solutions intended to improve the safety, compatibility, and availability of donated blood and plasma. The Point-of-Care segment offers rapid tests and analyzers that can produce results close to the patient in physician offices, hospitals, urgent-care centers, pharmacies, retail clinics, and other decentralized settings. Its Molecular Diagnostics activities include polymerase chain reaction thermocyclers, analyzers, amplification systems, and associated assays.
QuidelOrtho sells through a combination of direct commercial channels and distributors. Its customer base includes hospitals, clinical and reference laboratories, medical offices, universities, blood and donor centers, pharmacies, wellness-screening organizations, and individual consumers purchasing nonprofessional or over-the-counter products. The company has an international footprint covering North America, Europe, the Middle East, Africa, China, and other markets.
The supplied information indicates approximately 7,100 employees as of late 2023, placing the company in the 5,001-10,000 employee category. Brian J. Blaser serves as President and Chief Executive Officer and brings more than 25 years of senior leadership experience in in vitro diagnostics. Reported 2023 revenue was approximately $3.0 billion. The supplied trailing financial data shows a gross margin of about 44.6%, but also significant operating and net losses, reflecting profitability pressure, substantial intangible assets, acquisition-related effects, and the cost structure of a global diagnostics manufacturer. Research and development expense represented roughly 6.8% of trailing revenue, while selling, general, and administrative expense was approximately 28.8%. The company’s long-term opportunity is to integrate its diagnostic portfolio, expand automated laboratory and transfusion workflows, grow rapid and molecular testing, and improve operating performance while maintaining regulatory compliance, product quality, and reliable supply across healthcare markets.
Shenzhen Lifotronic Technology Co., Ltd.SHSE:688389Shanghai Runda Medical Technology Co., Ltd.SHSE:603108Thermo Fisher Scientific Inc.NYSE:TMOVarious single-source raw material and component suppliersAntibody and biological reagent producers (industry-level)Specialty chemical and membrane manufacturers (industry-level)
